IGFBP2 and acute myeloid leukemia: The IGFBP2-null bone marrow AML cells decreased AML development during secondary transplantation (Figure 4A-F) and had dramatically decreased AKT and STAT3 activation (Figure 4G) as was observed in the primary transplanted cells.